FFA
CRSP icon

Fairfield Financial Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Fairfield Financial Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-61
Closed -$2.69K – 313
2023
Q1 		$2.69K Sell
61
-56
-48% -$2.72K ﹤0.01% 290
2022
Q4 		$4.76K Hold
117
– – ﹤0.01% 254
2022
Q3 		$7.65K Hold
117
– – ﹤0.01% 236
2022
Q2 		$7.11K Hold
117
– – ﹤0.01% 227
2022
Q1 		$7.34K Buy
+117
New +$7.35K ﹤0.01% 241

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fairfield Financial Advisors's CRSP Position: Q2 2023 in Review

Fairfield Financial Advisors sold out of CRISPR Therapeutics (CRSP) in Q2 2023, closing a stake of 61 shares — an estimated $2.69K sold.

Fairfield Financial Advisors first reported a position in CRSP in Q1 2022 and held it in 5 quarters. The position peaked at $7.65K in Q3 2022. 418 funds tracked by Wall St. Rank hold CRSP as of Q2 2023.

  • Fairfield Financial Advisors reported no remaining CRISPR Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Fairfield Financial Advisors sold 61 CRISPR Therapeutics shares in Q2 2023, an estimated $2.69K.
  • Fairfield Financial Advisors first reported a position in CRISPR Therapeutics in Q1 2022 and held it in 5 quarters.
  • Fairfield Financial Advisors's CRISPR Therapeutics position peaked at $7.65K in Q3 2022.
  • 418 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2023.

Based on Fairfield Financial Advisors's 13F filing for Q2 2023, filed 4 Nov 2024.